Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro

Anesthesiology

Volumn 119, Issue 3, 2013, Pages 593-605

  Benzonana, Laura L ^a   Perry, Nicholas J S ^a   Watts, Helena R ^a   Yang, Bob ^a   Perry, Iain A ^a   Coombes, Charles ^a   Takata, Masao ^a   Ma, Daqing ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACTIN; ALPHA TUBULIN; COLLAGEN; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOFLURANE; PROTEIN KINASE B; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CHROMONE DERIVATIVE; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; INHALATION ANESTHETIC AGENT; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CELL MIGRATION; CYTOSKELETON; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; KIDNEY CANCER; KIDNEY CARCINOMA; PRIORITY JOURNAL; UPREGULATION; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; KIDNEY TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANESTHETICS, INHALATION; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL MOVEMENT; CELL PROLIFERATION; CHROMONES; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOFLURANE; KIDNEY NEOPLASMS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84883207049     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31829e47fd     Document Type: Article

References (49)

1. Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D: Cancer recurrence after surgery: Direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130: 1237-50
2. Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I: Increased surgical stress promotes tumor metastasis. Surgery 2003; 133: 547-55 (Pubitemid 36638227)
3. Boomsma MF, Garssen B, Slot E, Berbee M, Berkhof J, Meezenbroek Ede J, Slieker W, Visser A, Meijer S, Beelen RH: Breast cancer surgery-induced immunomodulation. J Surg Oncol 2010; 102: 640-8
4. Camara O, Kavallaris A, Nöschel H, Rengsberger M, Jörke C, Pachmann K: Seeding of epithelial cells into circulation during surgery for breast cancer: The fate of malignant and benign mobilized cells. World J Surg Oncol 2006; 4:67
5. Mori M, Mimori K, Ueo H, Karimine N, Barnard GF, Sugimachi K, Akiyoshi T: Molecular detection of circulating solid carcinoma cells in the peripheral blood: The concept of early systemic disease. Int J Cancer 1996; 68: 739-43 (Pubitemid 27062033)
6. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105: 660-4 (Pubitemid 44477309)
7. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE: Long-term survival after colon cancer surgery: A variation associated with choice of anesthesia. Anesth Analg 2008; 107: 325-32
8. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: A retrospective analysis. Anesthesiology 2008; 109: 180-7
9. Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W: Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: A retrospective analysis. Br J Anaesth 2011; 106: 814-22
10. Shapiro J, Jersky J, Katzav S, Feldman M, Segal S: Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. J Clin Invest 1981; 68: 678-85 (Pubitemid 11005043)
11. Huitink JM, Heimerikxs M, Nieuwland M, Loer SA, Brugman W, Velds A, Sie D, Kerkhoven RM: Volatile anesthetics modulate gene expression in breast and brain tumor cells. Anesth Analg 2010; 111: 1411-5
12. Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, Maze M: Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009; 20: 713-20
13. De Hert SG, Turani F, Mathur S, Stowe DF: Cardioprotection with volatile anesthetics: Mechanisms and clinical implications. Anesth Analg 2005; 100: 1584-93 (Pubitemid 40712704)
14. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32 (Pubitemid 37328811)
15. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21 (Pubitemid 30626905)
16. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-34
17. Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, Zhang J, Yao L, Guo G: HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 2010; 316: 1985-93
18. Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, Meng L, Lu Y, Ma D: Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol 2010; 136: 447-56
19. Ma D, Hossain M, Rajakumaraswamy N, Franks NP, Maze M: Combination of xenon and isoflurane produces a synergistic protective effect against oxygen-glucose deprivation injury in a neuronal-glial co-culture model. Anesthesiology 2003; 99: 748-51 (Pubitemid 37051994)
20. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5 (Pubitemid 29246458)
21. Semenza GL: Hydroxylation of HIF-1: Oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19: 176-82 (Pubitemid 39481932)
22. Semenza GL: Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-14
23. Raphael J, Zuo Z, Abedat S, Beeri R, Gozal Y: Isoflurane preconditioning decreases myocardial infarction in rabbits via up-regulation of hypoxia inducible factor 1 that is mediated by mammalian target of rapamycin. Anesthesiology 2008; 108: 415-25 (Pubitemid 351304235)
24. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-1 (Pubitemid 38796850)
25. Raphael J, Rivo J, Gozal Y: Isoflurane-induced myocardial preconditioning is dependent on phosphatidylinositol-3-kinase/ Akt signalling. Br J Anaesth 2005; 95: 756-63 (Pubitemid 41762373)
26. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-86 (Pubitemid 40853601)
27. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, Poellinger L, Påhlman S: Recruitment of HIF- 1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413-23 (Pubitemid 44693470)
28. Qing G, Simon MC: Hypoxia inducible factor-2alpha: A critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009; 19: 60-6
29. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr: Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1:E83
30. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-65 (Pubitemid 39295997)
31. Cervera AM, Apostolova N, Luna-Crespo F, Sanjuan-Pla A, Garcia-Bou R, McCreath KJ: An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett 2006; 233: 131-8 (Pubitemid 43214571)
32. Löfstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L, Påhlman S: Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007; 6: 919-26
33. Averous J, Proud CG: When translation meets transformation: The mTOR story. Oncogene 2006; 25: 6423-35 (Pubitemid 44582286)
34. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-4
35. Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G, Tanzi RE: The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 2006; 104: 988-94
36. Loop T, Dovi-Akue D, Frick M, Roesslein M, Egger L, Humar M, Hoetzel A, Schmidt R, Borner C, Pahl HL, Geiger KK, Pannen BH: Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology 2005; 102: 1147-57 (Pubitemid 40745833)
37. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF: Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004; 101: 703-9 (Pubitemid 39121650)
38. Bakar AM, Park SW, Kim M, Lee HT: Isoflurane protects against human endothelial cell apoptosis by inducing sphingosine kinase-1 via ERK MAPK. Int J Mol Sci 2012; 13: 977-93
39. Zhang L, Huang H, Cheng J, Liu J, Zhao H, Vizcaychipi MP, Ma D: Pre-treatment with isoflurane ameliorates renal ischemic- reperfusion injury in mice. Life Sci 2011; 88: 1102-7
40. Jamnicki-Abegg M, Weihrauch D, Pagel PS, Kersten JR, Bosnjak ZJ, Warltier DC, Bienengraeber MW: Isoflurane inhibits cardiac myocyte apoptosis during oxidative and inflammatory stress by activating Akt and enhancing Bcl-2 expression. Anesthesiology 2005; 103: 1006-14 (Pubitemid 41552056)
41. Xu Z, Dong Y, Wu X, Zhang J, McAuliffe S, Pan C, Zhang Y, Ichinose F, Yue Y, Xie Z: The potential dual effects of anesthetic isoflurane on Aβ-induced apoptosis. Curr Alzheimer Res 2011; 8: 741-52
42. Harato M, Huang L, Kondo F, Tsunekawa K, Feng GG, Fan JH, Ishikawa N, Fujiwara Y, Okada S: Bupivacaine-induced apoptosis independently of WDR35 expression in mouse neuroblastoma Neuro2a cells. BMC Neurosci 2012; 13:149
43. Unami A, Shinohara Y, Ichikawa T, Baba Y: Biochemical and microarray analyses of bupivacaine-induced apoptosis. J Toxicol Sci 2003; 28: 77-4
44. Lee HT, Xu H, Siegel CD, Krichevsky IE: Local anesthetics induce human renal cell apoptosis. Am J Nephrol 2003; 23: 129-39 (Pubitemid 36649329)
45. Suresh S: Biomechanics and biophysics of cancer cells. Acta Biomater 2007; 3: 413-38 (Pubitemid 46865787)
46. Olson MF, Sahai E: The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009; 26: 273-87
47. Small J, Rottner K, Hahne P, Anderson KI: Visualising the actin cytoskeleton. Microsc Res Tech 1999; 47: 3-7
48. Small JV, Kaverina I, Krylyshkina O, Rottner K: Cytoskeleton cross-talk during cell motility. FEBS Lett 1999; 452: 96-9 (Pubitemid 29257876)
49. Tojkander S, Gateva G, Lappalainen P: Actin stress fibers- Assembly, dynamics and biological roles. J Cell Sci 2012; 125(Pt 8): 1855-64